-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Onureg in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Onureg in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Onureg in Waldenstrom Macroglobulinemia (Lymphoplasmacytic Lymphoma) Drug Details: Azacitidine (Onureg)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ibudilast in Amyotrophic Lateral Sclerosis
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibudilast in Amyotrophic Lateral Sclerosis report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibudilast in Amyotrophic Lateral Sclerosis Drug Details: Ibudilast (Ketas) is an...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Ibudilast in Chemotherapy Induced Peripheral Neuropathy
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibudilast in Chemotherapy Induced Peripheral Neuropathy report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibudilast in Chemotherapy Induced Peripheral Neuropathy Drug Details: Ibudilast (Ketas)...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Bedoradrine Sulfate in Asthma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Bedoradrine Sulfate in Asthma report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Bedoradrine Sulfate in Asthma Drug Details: Bedoradrine sulfate (MN-221, KUR1246) is under...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Zanubrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Zanubrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Zanubrutinib in Relapsed Chronic Lymphocytic Leukemia (CLL) Drug...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ibudilast in Alcohol Dependence
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ibudilast in Alcohol Dependence report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ibudilast in Alcohol Dependence Drug Details: Ibudilast (Ketas) is an anti-inflammatory and...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – SC-291 in Primary Mediastinal B-Cell Lymphoma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - SC-291 in Primary Mediastinal B-Cell Lymphoma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. SC-291 in Primary Mediastinal B-Cell Lymphoma Drug Details: SC-291...
-
Product Insights
Ocular Melanoma – Drugs In Development, 2023
Global Markets Direct’s, ‘Ocular Melanoma - Drugs In Development, 2023’, provides an overview of the Ocular Melanoma pipeline landscape. The report provides comprehensive information on the therapeutics under development for Ocular Melanoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...
-
Product Insights
Alcohol Addiction – Drugs In Development, 2023
Global Markets Direct’s, ‘Alcohol Addiction - Drugs In Development, 2023’, provides an overview of the Alcohol Addiction pipeline landscape. The report provides comprehensive information on the therapeutics under development for Alcohol Addiction, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...